Status:
UNKNOWN
Long-Term Post Thrombotic Syndrome Assessment (CELEST Long Term).
Lead Sponsor:
Laboratoires Innothera
Collaborating Sponsors:
Floralis
Conditions:
Post Thrombotic Syndrome
Eligibility:
All Genders
18-100 years
Brief Summary
The CELEST Long term is a prospective study, assessing the very long term risk of post thrombotic syndrome (PTS) in patients enrolled in the CELEST double-blind RCT. All patients enrolled in CELEST RC...
Detailed Description
The CELEST double blind RCT demonstrated that 25mmHg elastic compression stockings (ECS) were non inferior to 35mmHg ECS to prevent post thrombotic syndrome (PTS) 2 years after a first proximal deep v...
Eligibility Criteria
Inclusion
- Patients enrolled and followed in the CELEST RCT\*
Exclusion
- Patients who withdrew consent or died during the 2-year follow-up of the CELEST RCT.
- Patients who decline or are unable to participate (including severe memory loss issues) to the long-term follow-up
- CELEST RCT main inclusion/exclusion criteria were: adult (\>18 years at time of enrolment) patients first unilateral acute symptomatic proximal lower limb DVT
Key Trial Info
Start Date :
July 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 24 2023
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT06046807
Start Date
July 24 2023
End Date
December 24 2023
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ROLLAND
Grenoble, France